Ozempic vs Wegovy (2026): Uses, Doses, Pills and Injection Costs
Ozempic and Wegovy contain semaglutide, but their labeled uses, doses and formulations differ. Both brands have injection and tablet presentations.
Compare the exact product, indication, supply and payment route; do not transfer dose or coverage assumptions between them.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01Are Ozempic and Wegovy the Same Drug?
- 02What Are Ozempic and Wegovy FDA Approved For?
- 03How Do Ozempic and Wegovy Doses Compare?
- 04What do the separate clinical trials show?
- 05What does SELECT show about cardiovascular risk?
- 06What Are the Side Effects?
- 07What do Ozempic and Wegovy cost by product and refill?
- 08Does Insurance Cover Ozempic or Wegovy?
- 09Available Formulations in 2026
- 10When should you discuss Ozempic with your prescriber?
- 11When should you discuss Wegovy with your prescriber?
- 12Can You Switch Between Ozempic and Wegovy?
- 13Frequently Asked Questions
- 14Our Bottom Line
Ozempic and Wegovy contain semaglutide, but their uses, formulations and dosing instructions differ. Both brands have injections and tablets.
Ozempic products have adult type 2 diabetes indications; Wegovy has weight-management and specified cardiovascular indications, with additional injection-specific uses.
A shared ingredient does not make prescriptions interchangeable. Compare the exact product with your prescriber, then check its formulary entry and complete bill.
For a quick comparison, start with the route you need:
- •Diabetes treatment: check the actual Ozempic injection or tablet indication and your plan’s requirements. Kidney-related claims for the injection do not automatically apply to tablets.
- •Weight management: discuss a labeled Wegovy presentation and eligibility with your clinician. Ozempic prescribed for weight loss is off-label; that does not assure insurance coverage.
- •A pill rather than an injection: compare product-specific administration and dosing in the oral GLP-1 guide. Milligrams cannot be transferred between tablets and injections.
- •The bill: the manufacturer’s starting price can change with strength and refill. Telehealth membership, medication and other services may be billed separately. The qualified price table below separates those questions.
The current Ozempic injection label, Ozempic/Rybelsus tablet label and Wegovy label define the distinctions below.
Use our coverage checklist for plan questions or provider comparison for program terms. Neither determines which medicine is clinically appropriate.
See what each one costs and how to get it
Each page lists who prescribes it and what you pay. Your prescriber decides which one suits you.
Check Ozempic costs →Are Ozempic and Wegovy the Same Drug?
Both contain semaglutide from Novo Nordisk, with different labeled uses and formulations.
For injections, Ozempic has a 2 mg weekly maximum and Wegovy has indication-specific maintenance doses, including a conditional 7.2 mg adult weight-reduction option. Tablets have separate strengths and instructions.
Use the label for the actual prescription rather than transferring a dose between forms.
Semaglutide is a GLP-1 receptor agonist, a synthetic version of a gut hormone that reduces appetite, slows gastric emptying, and improves blood sugar regulation.
Novo Nordisk developed it first for diabetes under the brand name Ozempic, which received FDA approval in December 2017.
When clinical trials showed significant weight loss as a side effect, Novo Nordisk ran a separate set of trials (the STEP program) at a higher dose and received a second FDA approval for weight management in June 2021 under the brand name Wegovy.
This two-brand strategy is common in pharma. The same molecule gets tested at different doses for different conditions and sold under different names with different pricing.
It's the reason so much confusion exists, patients hear about "Ozempic for weight loss" in the media but their doctor prescribes Wegovy, or vice versa.
Both work for weight loss, but the regulatory and practical differences are real and affect your wallet, your insurance coverage, and your dosing options.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Selected labeled uses | Injection: adult T2D glucose control, specified CV and kidney uses. Tablets: adult T2D glucose control and specified CV risk reduction; use the separate label | Weight management and specified CV risk reduction; injection also has an accelerated-approval MASH indication with defined fibrosis criteria |
| Route | Weekly injection or daily tablet; use the exact product label | Weekly subcutaneous injection OR daily oral tablet |
| Maximum dose (injectable) | 2 mg/week | 2.4 mg/week (standard) or 7.2 mg/week (Wegovy HD) |
| Year approved | 2017 (0.5/1 mg), 2022 (2 mg) | 2021 (injectable), Dec 2025 (oral), Mar 2026 (HD 7.2 mg) |
| Oral version available | Yes: Ozempic tablets 1.5 mg starting dose, then 4 or 9 mg; distinct from Rybelsus | Yes, oral Wegovy 25 mg daily tablet |
What Are Ozempic and Wegovy FDA Approved For?
Check the exact product and indication. The Ozempic injection label covers adult type 2 diabetes glucose control and specified cardiovascular and kidney-related uses.
The Ozempic/Rybelsus tablet label covers adult type 2 diabetes glucose control and specified cardiovascular risk reduction; it does not carry the injection’s kidney indication.
The Wegovy label includes weight reduction and maintenance in eligible adults, plus cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity.
Its injection also has weight-management use in eligible patients aged 12 and older and an accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) in adults.
Those pediatric and MASH indications must not be assigned to the tablet.
FDA guidance explains that a clinician may prescribe an approved medicine for an unapproved use when medically appropriate.
FDA has not established safety and effectiveness for that unapproved use. A prescription also does not establish insurer coverage.
Discuss the indication and the exact formulation separately; our Ozempic for PCOS guide addresses that specific question.
The cardiovascular indication requires established cardiovascular disease, not risk factors alone. A qualifying indication may provide a different coverage route, but your plan must still confirm its rules.
How Do Ozempic and Wegovy Doses Compare?
There is no universal tablet-to-injection or brand-to-brand conversion.
This adult injection comparison summarizes the Ozempic injection label and Wegovy label.
It is not a personal dosing schedule; tablets and other indications have their own instructions.
| Adult injection feature | Ozempic | Wegovy for weight reduction |
|---|---|---|
| Starting dose | 0.25 mg weekly for 4 weeks, then 0.5 mg weekly | 0.25 mg weekly for 4 weeks; the label then uses staged escalation |
| Later increases | Only if additional glucose control is needed: after at least 4 weeks at 0.5 mg, 1 mg may be used; after at least 4 weeks at 1 mg, 2 mg may be used | Follow the labeled escalation and tolerability instructions with the prescriber; do not treat a calendar week as an automatic increase |
| Maintenance | 0.5, 1 or 2 mg weekly for glucose control; the type 2 diabetes plus CKD indication specifies 1 mg after at least 4 weeks at 0.5 mg | 2.4 mg weekly is recommended; 1.7 mg is another adult weight-reduction maintenance option under the label |
| Maximum or conditional higher dose | 2 mg weekly | 7.2 mg only for adults after tolerating 2.4 mg for at least 4 weeks and when additional weight reduction is clinically indicated |
An Ozempic patient does not have to progress to 2 mg simply because more weeks have passed. Likewise, the presence of a 7.2 mg Wegovy product does not make that strength suitable for everyone.
Clinical response, indication and tolerability determine the discussion.
Wegovy tablets use 1.5, 4, 9 and 25 mg strengths; Ozempic tablets use 1.5, 4 and 9 mg; Rybelsus uses 3, 7 and 14 mg. These numbers are not dose equivalents.
The Ozempic/Rybelsus tablet label specifically distinguishes the Ozempic and Rybelsus formulations. Use the actual prescription instructions.
What do the separate clinical trials show?
Separate trials do not establish a personal or brand-to-brand outcome. STEP 1 and STEP UP studied adults with obesity or overweight under their specific entry criteria, without diabetes.
Ozempic’s glucose-control studies enrolled people with type 2 diabetes. Population, duration, comparator and analysis must stay attached to each result.
| Study and population | Duration and comparison | Reported mean weight change |
|---|---|---|
| STEP 1: adults with overweight or obesity, without diabetes | 68 weeks; weekly semaglutide 2.4 mg versus placebo, both with lifestyle intervention | 14.9% reduction versus 2.4% reduction in its primary analysis |
| STEP UP: adults with obesity, without diabetes | 72 weeks; weekly semaglutide 7.2 mg versus 2.4 mg versus placebo | Main treatment-policy analysis: 18.7% versus 15.6% versus 3.9% reduction |
| STEP UP: same study, different question | Trial-product analysis estimating continued treatment without rescue intervention | 20.7% versus 17.5% versus 2.4% reduction; do not substitute these for the main analysis |
Sources: STEP 1 primary report, STEP UP report and its sponsor plain-language summary.
These are group averages, not an Ozempic-versus-Wegovy head-to-head trial or a prediction for someone switching products.
Do not subtract results from different trials to estimate the benefit of a new prescription. For a different-molecule comparison with its own evidence limits, see Wegovy versus Zepbound.
The semaglutide timeline guide explains how to read follow-up periods.
What does SELECT show about cardiovascular risk?
The SELECT trial enrolled 17,604 adults aged at least 45 with established cardiovascular disease and overweight or obesity, without diabetes.
Weekly semaglutide 2.4 mg was compared with placebo.
The primary composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% versus 8.0% over a mean follow-up of about 40 months; the hazard ratio was 0.80, commonly described as a 20% relative risk reduction.
That is evidence for a specified population and outcome, not proof that any person with cardiovascular risk factors qualifies.
The current Wegovy label requires established cardiovascular disease and overweight or obesity for its cardiovascular indication.
Ozempic’s cardiovascular indications have their own type 2 diabetes criteria, with formulation-specific wording.
Ask your clinician whether you meet the indication and your plan how that indication is covered. The clinical evidence does not guarantee authorization or a particular copay.
What Are the Side Effects?
Nausea, vomiting, diarrhea, abdominal pain and constipation are among the common adverse reactions listed in the Ozempic injection label, Ozempic/Rybelsus tablet label and Wegovy label.
Sharing semaglutide does not establish identical adverse-event rates or make one presentation safer for a particular patient.
Rates from different trial populations, doses and follow-up periods cannot be read as a direct safety ranking.
Use the safety information for your prescribed presentation and tell your clinician about persistent or severe symptoms rather than changing the dose or switching brands yourself.
The labels carry boxed warnings about thyroid C-cell tumors in rodents; whether semaglutide causes these tumors in humans is unknown.
They contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Other warnings include pancreatitis, gallbladder disease, volume-depletion-related kidney injury, severe gastrointestinal reactions and hypoglycemia with certain diabetes medicines.
The complete warnings and contraindications are product-specific.
Tell the treating team about other medicines, pregnancy plans, eye disease and planned anesthesia or procedures.
The side-effect discussion guide can help you prepare questions; urgent or severe symptoms need medical assessment.
What do Ozempic and Wegovy cost by product and refill?
A starting price is not a permanent price or a complete telehealth bill. The offers below come from NovoCare delivery terms.
For the introductory injection offers, the prescription must be written and received by December 31, 2026, and shipped by January 31, 2027. They require a prescription and eligibility; the manufacturer may change or end them.
Confirm the exact strength, supply and next fill before paying.
| Product | Eligible self-pay offer | Supply and later-fill conditions |
|---|---|---|
| Ozempic injection | No previous Ozempic injection fill through NovoCare or NovoCare Legacy: $199 each for up to two 28-day 0.25 or 0.5 mg home-delivery fills | Then $349 for 0.25, 0.5 or 1 mg; $499 for 2 mg. A month is 1 box of 1 pen |
| Wegovy injection | No previous Wegovy injection fill through NovoCare or NovoCare Legacy: $199 each for up to two 28-day 0.25 or 0.5 mg home-delivery fills | Then $349 for standard strengths 0.25–2.4 mg; $399 for HD 7.2 mg. A month is 1 box of 4 weekly pens |
| Ozempic tablets | From $149; price depends on prescribed dose | A month is 30 tablets. The delivery page does not specify the 4 or 9 mg price; confirm the quote |
| Wegovy tablets | $149 for 1.5 mg; $199 for 4 mg; $299 for 9 or 25 mg | Each month is 1 bottle of 30 tablets. A starting-strength price does not apply to every maintenance strength |
Eligible commercially insured patients may pay as little as $25 under the separate savings-card terms, subject to a maximum saving of $100 per month and other restrictions.
Government beneficiaries are excluded from these commercial offers. A minimum copay headline is not a guaranteed final price.
A telehealth program may charge membership separately from medication. See Ro’s membership and medication breakdown; do not read a drug-only subscription quote as Ro’s complete bill.
Compare the actual term, amount due today, renewal and included services.
For Medicare, the separate GLP-1 Bridge guide explains eligible Wegovy access and its $50 monthly copay after approval.
That is not ordinary Part D coverage for weight loss, not an Ozempic offer and not a manufacturer commercial savings card.
The cost calculator can help organize scenarios. It is an estimate, not an insurer decision or a dispensing quote.
Does Insurance Cover Ozempic or Wegovy?
Coverage depends on the exact medicine, formulation, indication and plan. A prescription does not establish coverage.
Ask for the current formulary entry, prior-authorization requirements, copay or coinsurance and dispensing restrictions for the specific product.
- •Commercial coverage: ask about each product separately. A plan’s Ozempic diabetes coverage does not mean it covers Wegovy for weight management, and a savings-card minimum does not assure your final bill.
- •Medicare: approved diabetes-related uses may follow ordinary Part D rules. The separate GLP-1 Bridge can provide eligible Wegovy weight-management access for a $50 monthly copay after approval; it is not ordinary Part D weight-loss coverage and Ozempic is not a Bridge product.
- •Medicaid: check the state program and current drug list for the actual product and indication. Do not transfer another state’s answer to your plan.
- •A cardiovascular indication: established cardiovascular disease and overweight or obesity may satisfy Wegovy’s labeled clinical criteria, subject to the full label. It is not a workaround or a reason to change a diagnosis for billing.
Use the insurance lookup checklist to prepare those questions. If both products are covered, clinical suitability still comes first.
If neither is covered, compare the qualified cash terms and any separate program fees rather than choosing by a starting-price headline.
Official references: Medicare weight-loss drug coverage, CMS GLP-1 Bridge rules and the current product labels.
Available Formulations in 2026
These selected US-labeled formulations have different strengths and instructions. This is a product comparison, not a live pharmacy-stock check.
Read the Ozempic injection label, Ozempic/Rybelsus tablet label and Wegovy label for the prescribed product.
| Product | Formulation | Doses | Approved For | Available |
|---|---|---|---|---|
| Ozempic tablets | Daily tablet | 1.5 mg starting dose; 4 or 9 mg | Adult T2D glucose control; specified CV risk reduction | Current US label; confirm stock |
| Ozempic | Weekly injection pen | 0.25, 0.5, 1, 2 mg | Type 2 diabetes | Since 2017 |
| Wegovy | Weekly injection pen | 0.25, 0.5, 1, 1.7, 2.4 mg | Weight management, CV risk reduction | Since 2021 |
| Wegovy HD | Weekly injection pen | 7.2 mg; adult label conditions apply | Weight management | April 2026 |
| Oral Wegovy | Daily tablet | 1.5, 4, 9, 25 mg | Weight management, CV risk reduction | January 2026 |
| Rybelsus | Daily tablet | 3, 7, 14 mg | Type 2 diabetes | Since 2019 |
Ozempic injection and tablets are diabetes-indicated products; Wegovy has weight-management presentations. Ozempic tablets and Rybelsus are different oral semaglutide formulations and are not substitutable milligram for milligram.
Your clinician must choose the actual product and dosing instructions; a shared ingredient is not a substitution rule.
The oral Wegovy tablet, approved in December 2025, reported a 13.6% mean weight reduction at week 64 in the OASIS 4 trial, against 2.2% on placebo.
The higher 16.6% figure you may see quoted estimates the result if everyone had stayed on treatment.
It must be taken on an empty stomach with a small amount of water, then you wait 30 minutes before eating or drinking anything else.
This fasting requirement is the main downside compared to pills like Foundayo (orforglipron), which has no fasting requirement.
NovoCare now lists an Ozempic pill from $149/month as well as the pen from $199/month, with a prescription and dose-dependent pricing.
Rybelsus remains a separate oral semaglutide diabetes brand at different doses, and oral Wegovy is the weight-management brand.
Do not treat Ozempic, Rybelsus, and Wegovy tablets as interchangeable simply because each uses semaglutide.
When should you discuss Ozempic with your prescriber?
Ozempic may be part of an adult type 2 diabetes treatment discussion.
Ask which formulation and indication apply: the Ozempic injection label and Ozempic/Rybelsus tablet label have different strengths and selected uses.
Your clinician, not this comparison, determines suitability.
- •Glucose, heart and kidney goals: confirm the actual indication. The injection’s kidney-related indication must not be assigned to its tablet.
- •Existing coverage: ask your plan about the precise product and authorization requirements; coverage of one presentation may not transfer to another.
- •An existing prescription: review response, tolerability and other medicines with the prescriber. Do not use Ozempic as an informal tolerability test before switching to Wegovy.
If the question involves a different molecule for diabetes, our Mounjaro versus Ozempic comparison distinguishes that trial context from obesity studies.
When should you discuss Wegovy with your prescriber?
Wegovy has labeled weight-management presentations for eligible patients and a specified cardiovascular indication.
The Wegovy label sets the age, indication, formulation and dosing conditions; a larger maximum dose is not by itself a reason to select it.
- •Weight management: discuss the full eligibility criteria, appropriate presentation and follow-up, including whether an injection or tablet fits the treatment plan.
- •Established cardiovascular disease: ask whether the cardiovascular indication applies alongside overweight or obesity. Risk factors alone are not the same criterion.
- •A tablet preference: consider fasting instructions, other medicines and the prescribed-strength total, not just the starting pill price.
- •Medicare access: check the separate Bridge’s enrollment, clinical and authorization requirements. Ordinary Part D rules and manufacturer commercial offers are different routes.
Bring the formulation and full price quote to that discussion. The comparison cannot identify a universally best product or predict an individual’s weight loss.
Can You Switch Between Ozempic and Wegovy?
A prescriber can consider a switch, but sharing the semaglutide molecule does not create a universal dose-conversion rule. The current product, indication, dose, time since the last dose and tolerability determine the transition.
Consult the current Wegovy prescribing information with your clinician.
Common switching scenarios include:
- •Ozempic to Wegovy: Confirm the intended indication and formulation with your prescriber. Do not match the dose yourself or assume insurance approval transfers between products.
- •Wegovy to Ozempic: A supply or coverage change requires a new clinical and coverage assessment, not an automatic substitute.
- •Injectable to oral: Use the prescriber-directed, product-specific transition in the current label. For a new Wegovy tablet start, the labeled ladder is 1.5, 4, 9 and 25 mg, not the older Rybelsus 3/7/14 mg sequence. A switch is not necessarily a new start.
Never switch medications without your prescriber's guidance.
While Ozempic and Wegovy contain the same active ingredient, the dose equivalences aren't always 1:1 (especially between injectable and oral forms), and your provider needs to manage the transition based on your individual response and tolerability.
Frequently Asked Questions
Is Ozempic or Wegovy better for weight loss?
Wegovy has labeled weight-management presentations; Ozempic has diabetes-related indications. Separate studies do not prove the brands produce identical results at an assumed equivalent dose.
Discuss the actual product and clinical goals with your prescriber; the trial table above preserves population, duration and analysis.
Can I use Ozempic for weight loss if I don't have diabetes?
FDA explains that clinicians may prescribe an approved medicine for an unapproved use when medically appropriate.
Ozempic for weight loss is off-label; FDA has not established its safety and effectiveness for that use, and a prescription does not guarantee insurance coverage. Ask about labeled weight-management options as well.
Do Ozempic and Wegovy have the same side effects?
Both labels list gastrointestinal adverse reactions and significant warnings, but that does not establish identical rates or individual tolerability.
Read the Ozempic injection label, Ozempic/Rybelsus tablet label or Wegovy label for the exact prescribed presentation.
Different trials are not a head-to-head safety comparison.
Why are there different brands with the same ingredient?
The brands have product-specific approvals, presentations, strengths and instructions. A shared ingredient does not replace those distinctions or determine formulary coverage.
Match the exact prescription to its label and payment route.
Will Wegovy work if Ozempic didn't work for me?
The studies summarized here cannot predict an individual’s response to a switch. Review the reason for the limited response, prescribed product, treatment history, tolerability and other medicines with the clinician.
Do not infer a benefit by subtracting doses or trial percentages.
Is compounded semaglutide a generic Ozempic or Wegovy?
No. Compounded semaglutide is not an FDA-approved generic of either brand.
FDA’s February 21, 2025 shortage-resolution decision is separate from generic approval and affects conditions for compounding copies of approved medicines.
Our brand versus compounded guide explains that distinction.
The FDA announcement resolving the semaglutide injection shortage is dated February 21, 2025. An earlier version of this article incorrectly placed it in late 2024.
Our Bottom Line
Start with the exact product and clinical indication, then compare coverage and the complete bill. Ozempic and Wegovy share an ingredient; their formulations, labeled uses and instructions still matter.
Neither a lower starting price nor a higher maximum dose determines which treatment is appropriate.
For the next administrative step, use the coverage checklist, Ro pricing breakdown or provider comparison.
The match quiz filters recorded program features and the cost calculator models scenarios. They cannot confirm medical suitability, insurer approval or an exact pharmacy price.
This article supports an informed discussion, not a personal treatment plan. Do not start, stop, change a dose or switch products without the prescriber.
Read the current label and complete offer terms for the actual prescription; eligibility, availability and prices can change.
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Where to go next
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.
Read the Medicare guide →What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
“Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before. The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity.”
“Patients on both medications experienced substantial weight loss, and we observed no difference in the risk of gastrointestinal adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.
